Cue Biopharma (CUE) News Today $1.31 +0.03 (+2.34%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Genmab A/S (OTCMKTS:GNMSF) & Cue Biopharma (NASDAQ:CUE) Financial ReviewJanuary 19 at 2:21 AM | americanbankingnews.comCue Biopharma, Inc. (NASDAQ:CUE) Short Interest UpdateCue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 1,080,000 shares, an increase of 8.0% from the November 30th total of 1,000,000 shares. Based on an average trading volume of 787,600 shares, the short-interest ratio is currently 1.4 days.January 2, 2025 | marketbeat.comCue Biopharma, Inc. (NASDAQ:CUE) CEO Acquires $30,900.00 in StockDecember 19, 2024 | insidertrades.comCue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in StockCue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) CEO Daniel R. Passeri purchased 30,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The stock was acquired at an average cost of $1.03 per share, with a total value of $30,900.00. Following the transaction, the chief executive officer now directly owns 164,578 shares of the company's stock, valued at approximately $169,515.34. This represents a 22.29 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.December 18, 2024 | marketbeat.comShort Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5%Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 1,000,000 shares, a decline of 6.5% from the November 15th total of 1,070,000 shares. Based on an average daily trading volume, of 762,400 shares, the days-to-cover ratio is presently 1.3 days.December 16, 2024 | marketbeat.comCue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 29, 2024 | markets.businessinsider.comCue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 29, 2024 | globenewswire.comCue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | markets.businessinsider.comCue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Cue Biopharma (CUE)November 18, 2024 | markets.businessinsider.comCue Biopharma Third Quarter 2024 Earnings: Beats ExpectationsNovember 17, 2024 | finance.yahoo.comCue Biopharma, Inc.: Cue Biopharma Announces Strategic Organizational TransitionNovember 16, 2024 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 16, 2024 | finanznachrichten.deCue Biopharma Reports Increased Revenue Amid Ongoing LossesNovember 16, 2024 | markets.businessinsider.comCue Biopharma’s Nasdaq Compliance Struggle: Risks and Implications for Future StabilityNovember 16, 2024 | markets.businessinsider.comCue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | globenewswire.comCue names Daniel Baker interim CDO, CSO Amish Suri to transition to advisor roleNovember 14, 2024 | markets.businessinsider.comCue Biopharma Announces Strategic Organizational TransitionNovember 14, 2024 | markets.businessinsider.comCue Biopharma Announces Strategic Organizational TransitionNovember 14, 2024 | globenewswire.comCue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare ConferenceNovember 12, 2024 | finance.yahoo.comCue Biopharma: Strategic Shift and Promising Clinical Results Support Buy RecommendationNovember 12, 2024 | markets.businessinsider.comCue Biopharma presents ‘positive’ update from Phase 1 trials of CUE-101, CUE-102November 8, 2024 | markets.businessinsider.comCue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual MeetingNovember 8, 2024 | globenewswire.comShort Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Drops By 48.7%Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 1,950,000 shares, a drop of 48.7% from the September 30th total of 3,800,000 shares. Based on an average daily trading volume, of 677,200 shares, the short-interest ratio is currently 2.9 days.October 26, 2024 | marketbeat.comCue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%October 8, 2024 | finance.yahoo.comCue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingOctober 4, 2024 | globenewswire.comCue Biopharma (NASDAQ:CUE) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comCue Biopharma (NASDAQ:CUE) Stock, Short Interest ReportSeptember 27, 2024 | benzinga.comCue Biopharma Announces Proposed Public OfferingSeptember 27, 2024 | finance.yahoo.comCue Biopharma Announces Pricing of $12.0 Million Public OfferingSeptember 26, 2024 | globenewswire.comCue Biopharma Announces Proposed Public OfferingSeptember 26, 2024 | globenewswire.comCue Biopharma Announces Proposed Public OfferingSeptember 26, 2024 | globenewswire.comCue Biopharma names Lucinda Warren as new chief business officerSeptember 11, 2024 | uk.investing.comCue Biopharma, Inc.: Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business OfficerSeptember 9, 2024 | finanznachrichten.deCue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business OfficerSeptember 9, 2024 | finance.yahoo.comCue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business OfficerSeptember 9, 2024 | globenewswire.comCue Biopharma to Present at The Promise of Interleukin-2 Therapy ConferenceSeptember 3, 2024 | finance.yahoo.comQ2 2024 Cue Biopharma Inc Earnings CallAugust 20, 2024 | ca.finance.yahoo.comCue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 20, 2024 | markets.businessinsider.comCue Biopharma, Inc. (NASDAQ:CUE) Q2 2024 Earnings Call TranscriptAugust 20, 2024 | msn.comCue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 19, 2024 | globenewswire.comCuts at Cue Biopharma include CEO salary, 25% of jobsJuly 26, 2024 | bizjournals.comCue Biopharma Receives ‘Buy’ Rating Amid Strategic Shift and Promising Autoimmune Therapeutics PipelineJuly 26, 2024 | markets.businessinsider.comCue Biopharma downsizes to focus on autoimmune pipelineJuly 26, 2024 | finance.yahoo.comApplied Intuition raises $300M four months after raising $250MJuly 25, 2024 | uk.finance.yahoo.comCue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital RequirementsJuly 25, 2024 | finance.yahoo.comCue Biopharma, Inc. (NASDAQ:CUE) Sees Significant Decrease in Short InterestCue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 4,590,000 shares, a decline of 7.5% from the April 30th total of 4,960,000 shares. Based on an average daily volume of 295,700 shares, the short-interest ratio is currently 15.5 days.June 2, 2024 | marketbeat.comMedical Moonshots: 3 Biotech Stocks Set to SkyrocketMay 30, 2024 | investorplace.comCue Biopharma’s Promising Future: A Comprehensive Buy Rating JustificationMay 16, 2024 | markets.businessinsider.comCue Biopharma First Quarter 2024 Earnings: Beats ExpectationsMay 11, 2024 | finance.yahoo.com Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address CUE Media Mentions By Week CUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CUE News Sentiment▼0.000.46▲Average Medical News Sentiment CUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CUE Articles This Week▼11▲CUE Articles Average Week Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Neumora Therapeutics News MBX Biosciences News Precigen News Olema Pharmaceuticals News Corvus Pharmaceuticals News Contineum Therapeutics News Chimerix News LifeVantage News enGene News Taysha Gene Therapies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CUE) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
